Qian Zhao, Teng Wang, Huanhuan Wang, Cheng Cui, Wen Zhong, Diyi Fu, . . . Pei Hu. (2022). Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma. Frontiers Media S.A..
Chicago Style (17th ed.) CitationQian Zhao, et al. Phase I Pharmacokinetic Study of an Oral, Small-molecule MEK Inhibitor Tunlametinib in Patients with Advanced NRAS Mutant Melanoma. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationQian Zhao, et al. Phase I Pharmacokinetic Study of an Oral, Small-molecule MEK Inhibitor Tunlametinib in Patients with Advanced NRAS Mutant Melanoma. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.